Oncoproteins - OmicsDI

Show results for

Unknown (1085)
Genomics (289)
Transcriptomics (243)
Proteomics (50)
Other (18)
Metabolomics (3)
Models (1)
Methylation profiling (1)

Organisms

Homo sapiens (249)
Mus musculus (113)
Drosophila melanogaster (7)
Rattus norvegicus (4)
Danio rerio (2)
Saccharomyces cerevisiae (2)
Gallus gallus (1)
Human papillomavirus 16 (1)
human papillomavirus 18 (1)

Organisms

Homo sapiens (127)
Mus musculus (63)
Drosophila melanogaster (4)
Rattus norvegicus (1)

Repository

ENA (228)
geo (206)
biostudies-arrayexpress (111)
pride (34)
EGA (8)
iProX (6)
MassIVE (5)
MetaboLights (3)
BioModels (1)
jPOST (1)
PanoramaPublic (1)
PeptideAtlas (1)

Tissue

Cell culture (15)
Epithelial cell (6)
Permanent cell line cell (3)
Early embryonic cell (2)
Kidney (2)
Others (1)
Blood (1)
Blood cell (1)
Colon epithelial cell (1)
Diploid cell (1)
Gastric adenocarcinoma cell (1)
HEK-293T cell (1)
HeLa cell (1)
Keratinocyte (1)
Lung (1)
Pancreatic ductal adenocarcinoma cell (1)
Pancreatic ductal cell (1)
Primary cell (1)

Disease

Neuroblastoma (3)
Acute leukemia (2)
Breast cancer (2)
Cervix carcinoma (2)
Imatinib-resistant CML cell line subclone (1)
Osteosarcoma (1)
Brain glioma (1)
Colorectal carcinoma (1)
Disease free (1)
Gastric adenocarcinoma (1)
Lung cancer (1)
Lymphoma (1)
Merkel cell carcinoma (1)
Multiple myeloma (1)
Non-small cell lung carcinoma (1)
Pancreatic ductal adenocarcinoma (1)
Skin cancer (1)
Skin melanoma (1)
Thyroid gland follicular carcinoma (1)
Urinary bladder cancer (1)

Technology Type

Mass Spectrometry (34)
Shotgun proteomics (18)
Affinity purification coupled with mass spectrometry proteomics (12)
Bottom-up proteomics (5)
Mass spectrometry assay (2)
Data-dependent acquisition (2)
Gel-based experiment (2)
ILLUMINA, NextSeq 500 (1)
Illumina HiSeq 2500, Illumina HiSeq 2000 (1)
NextSeq 500, Illumina HiSeq 2000, ILLUMINA (1)
NMR spectroscopy (1)
Affinity proteomics (1)
SRM/MRM (1)
SWATH MS (1)
Top-down proteomics (1)

Instrument Platform

IScan Illumina (1)
NextSeq 500 (1)
LTQ Orbitrap Velos (1)
Orbitrap Ascend (1)
Orbitrap Fusion (1)
Orbitrap Fusion Lumos (1)
Q Exactive (1)
TimsTOF (1)
Liquid Chromatography MS - negative - reverse-phase (1)
Liquid Chromatography MS - positive - reverse phase (1)
Liquid Chromatography MS - positive - reverse-phase (1)
Nuclear Magnetic Resonance (NMR) (1)
LTQ (1)

Publication Date

2014 (52)
2025 (42)
2022 (39)
2024 (29)
2026 (25)
2023 (23)
2013 (22)
2011 (15)
2021 (14)
2012 (14)
2015 (13)
2008 (13)
2020 (12)
2009 (11)
2016 (10)
2010 (9)
2019 (7)
2018 (5)
2005 (4)
2017 (4)
2007 (3)
2003 (1)

UNIPROT ID/AC

A5A3E0 (1)
A6NHR9 (1)
B0I1T2 (1)
B1AK88 (1)
B1AP13 (1)
B4E3A4 (1)
B7Z556 (1)
G5E972 (1)
G8JLB6 (1)
H0YJH7 (1)
I3L4N8 (1)
J9JID7 (1)
O00161 (1)
O00567 (1)
O15144 (1)
O15533 (1)
O43684 (1)
O43684-2 (1)
O60318 (1)
O75083 (1)
O75367 (1)
O75367-2 (1)
O75380 (1)
O75475 (1)
O75475-2 (1)
O75475-3 (1)
O75694 (1)
O76021 (1)
O96019 (1)
P02765 (1)

CHEBI ID

CHEBI:15367 (1)
CHEBI:15366 (1)
CHEBI:15428 (1)
CHEBI:15603 (1)
CHEBI:15741 (1)
CHEBI:16015 (1)
CHEBI:16414 (1)
CHEBI:16977 (1)
CHEBI:17053 (1)
CHEBI:17115 (1)
CHEBI:17191 (1)
CHEBI:17203 (1)
CHEBI:17295 (1)
CHEBI:17895 (1)
CHEBI:18050 (1)
CHEBI:30915 (1)
CHEBI:32816 (1)
CHEBI:4167 (1)
CHEBI:422 (1)

Metabolite Name

D-Glucose (2)
Succinic acid (2)
(10betaH,11xi)-11-Hydroxy-13-nor-6-eremophilen-8-one (1)
(1S,2R,4aR,8aR)-1-Acetoxy-7-isopropylidene-1,4a-dimethyl-6-oxodecahydro-2-naphthalenyl 2,3-dimethyl-2-oxiranecarboxylate (1)
(2-Amino-4-Methyl-6-Oxo-1,6-Dihydropyrimidin-5-Yl)Acetic Acid (1)
(2E)-3-(1H-Indol-2-Yl)Prop-2-Enoic Acid (1)
(2Z)-2-benzoxazol-2-yl-3-(4-hydroxy-3-methoxyphenyl)-1-(4-methylphenyl)prop-2- en-1-one (1)
(3E,5Z)-1,3,5-Heptatriene (1)
(3R,3aR,7aS)-3-Butylhexahydro-1(3H)-isobenzofuranone (1)
(4E)-7-Acetoxy-6-hydroxy-2-methyl-10-oxo-3,6,7,8,9,10-hexahydro-2H-oxecin-3-yl (2E)-2-butenoate (1)
(6,6-Dimethylbicyclo[3.1.1]hept-2-yl)methyl 6-O-[(2R,3R,4R)-3,4-dihydroxy-4-(hydroxymethyl)tetrahydro-2-furanyl]-beta-D-glucopyranoside (1)
(6-chloro-2-iminochromen-3-yl)-N-(4-ethylphenyl)carboxamide (1)
(6R,8Z)-6-Hydroxy-3-oxotetradecenoic acid (1)
(7,8-dimethoxy-2,2,3-trimethyl-2,3-dihydro-1H-benzo[d]azepin-4-yl)(3,4-dimethoxyphenyl)methanone (1)
(7E)-3-Isobutyl-13-methoxy-4,5,8-trimethyl-3,3a,4,6a,9,10,11,12,13,14-decahydro-1H-cycloundeca[d]isoindole-1,15(2H)-dione (1)
(E)-5-(3,4,5,6-Tetrahydro-3-pyridylidenemethyl)-2-furanmethanol (1)
(R)-2-Hydroxycaprylic acid (1)
(R)-3-Hydroxydodecanoic acid (1)
(R)-alpha-Methylhistamine (1)
(S)-10,16-Dihydroxyhexadecanoic acid (1)
(S)-3-(4-(2-(2-(hydroxymethyl)pyrrolidin-1-yl)-2-oxoethoxy)phenyl)-8-methoxy-2H-chromen-2-one (1)
(S)-3-Hydroxybutyric acid (1)
(S)-7-(2-(2-(hydroxymethyl)pyrrolidin-1-yl)-2-oxoethoxy)-2-methyl-3-phenyl-4H-chromen-4-one (1)
(S)-Actinidine (1)
(Z)-13-Oxo-9-octadecenoic acid (1)
(Z)-2-((Z)-1-(hydroxyimino)ethyl)-6,6-dimethylbicyclo[3.1.0]hexan-3-one oxime (1)
(Z)-5-[(2R,3S,4S)-4-Hydroxy-2-[(E)-3-hydroxyoct-1-enyl]oxan-3-yl]pent-3-enoic acid (1)
1(2H)-Naphthalenone, 3,4-dihydro-2-((4-methoxyphenyl)methylene)-, (E)- (1)
1,2,3,4,Tetrahydro-1,5,7-trimethylnapthalene (1)
1,2,3,4-Tetrahydroisoquinoline-1-carboxylic acid (1)

IsPrivate

False (1)

First Public Date

2014 (46)
2025 (31)
2022 (31)
2024 (26)
2026 (23)
2023 (21)
2020 (12)
2021 (10)
2019 (7)
2015 (7)
2018 (6)
2017 (5)
2016 (2)
2013 (1)

Modelling Approach

Multi-value logic model (1)

Modification

15.994915 (1)
57.021464 (1)
71.037114 (1)

Study type

Transcription profiling by array (80)
RNA-seq of coding RNA (11)
ChIP-seq (9)
Unknown experiment type (2)
ChIP-chip by tiling array (2)
Transcription profiling by tiling array (2)
Cell line - One-color microarray (1)
RNAi profiling by array (1)
Comparative genomic hybridization by array (1)
Methylation profiling by array (1)
Proteomic profiling by array (1)

Release Date

2021 (116)
2022 (98)
2020 (89)
2024 (80)
2014 (79)
2023 (76)
2018 (74)
2019 (70)
2025 (68)
2015 (66)
2016 (63)
2013 (56)
2017 (49)
2012 (41)
2011 (32)
2009 (30)
2008 (24)
2010 (23)
2007 (16)
2005 (7)
2026 (7)
2000 (7)
2003 (6)
2006 (3)
2004 (3)
2002 (3)
2001 (3)
1999 (3)
1997 (3)

Lab affiliation

Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, 75390, TX, USA (2)
1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA. 2Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA. 3Biological and Biomedical Sciences Program, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. (1)
Associate Professor of Biochemistry & Molecular Biology, Director Proteomics Core, Indiana University School of Medicine (1)
Biotechnology and Cell Signaling (CNRS/Université de Strasbourg, UMR 7242), Ecole Supérieure de Biotechnologie de Strasbourg, 300 Boulevard Sébastien Brant, 67400 Illkirch, France. (1)
Center for Systems Biology and Molecular Medicine, Yenepoya (Deemed to be University), Mangalore 575018, India (1)
Chair of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany (1)
Children's Hospital of Philadelphia Division of Oncology and Center for Childhood Cancer Research USA (1)
DKFZ F130 Division of Immunotherapy and Immunoprevention (1)
Department of Integrated Immunobiology Duke School of Medicine Durham, NC, USA (1)
Department of Medicine (GI Oncology), UCSF, United States (1)
Department of Obstetrics and Gynecology, Nagoya University, Aichi, Japan (1)
Department of Obstetrics and Gynecology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai Jiao Tong University School of medicine (1)
Department of Oncology and Children's Research Center, University Children's Hospital of Zurich, Zurich, Switzerland (1)
Department of Pathology, St. Jude Children’s Research Hospital, Memphis, Tennessee, 38105 USA (1)
Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China Frontier Science Center for Immunology and Metabolism, Medical Research Institute, Wuhan University, Wuhan 430071, China (1)
Department of Urology,Zhongnan Hospital of Wuhan University,Wuhan 430071,China. Frontier Science Center for Immunology and Metabolism,Medical Research Institute,Wuhan University,Wuhan 430071,China. (1)
Functional Proteomics, ICR (1)
Head of the Department, Proteomics Core (1)
IRIC-Université de Montréal (1)
Institute of Molecular Biology, Ackermannweg 4, 55128 Mainz (1)
MD Anderson Cancer Center (1)
Marian A. Messerschmidt Professor of Oncology Associate Director, McArdle Laboratory for Cancer Research,UW Madison (1)
Max-Planck-Institute of Biochemistry, Martinsried (1)
Medical University of Vienna (1)
Molecular Therapy of Virus-Associated Cancers, German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany (1)
Professor i molekylærbiologi og faglig leder av PROMEC Institutt for klinisk og molekylær medisin Erling Skjalgssons g 1, aboratoriesenteret * * Laboratoriesenter Norwegian University of Science and Technology Trondheim 7030 Norway ( lab head ) (1)
Sahlgrenska Academy, University of Gothenburg, Sweden (1)
Sahlgrenska Center for Cancer Research Department of Laboratory Medicine Institute of Biomedicine Sahlgrenska Academy at University of Gothenburg Gothenburg, Sweden (1)
Senior Scientist Project manager Core Facility for Medical Bioanalytics Proteomics Platform Tübingen (PxP) Institute for Ophthalmic Research Eberhard-Karls University of Tuebingen Elfriede-Aulhorn-Str. 7 D-72076 Tuebingen. Germany. (1)
Senior Scientist, BC Cancer, Vancouver, Canada (1)

Previous page
1 / 169
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 169
Next page

Sort by:

Relevance

Page size

RIT1 oncoproteins escape LZTR1-mediated proteolysis

These data accompany our publication "RIT1 oncoproteins escape LZTR1-mediated proteolysis" (Castel P., et al. Science, 2019). Experiment 1: Identification of LZTR1 as an interacting partner of RIT1 Q Exactive Plus P20161208-02 FLAG GFP P20161208-03 FLAG RIT1 LTQ Orbitrap Velos ...

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

2019-02-14 | MSV000083444 | MassIVE

Transgenic SCLC induced by E6/E7 oncoproteins vs normal controls

The human papillomavirus virus (HPV) is a proven cause of most human cervical cancers, and might have a role in other malignancies including vulva, skin, oesophagus, head and neck cancer. HPV has also been speculated to have a role in the pathogenesis of lung cancer. To validate the hypothesis of HP...

ORGANISM(S): Mus musculus

2014-05-27 | E-GEOD-23962 | biostudies-arrayexpress

FET fusion oncoproteins enrich SWI/SNF complex subtypes and interaction partners

• Abstract: FET fusion oncoproteins, containing the N-terminal of a FET protein (FUS, EWSR1 and TAF15) together with a DNA-binding transcription factor partner, are characteristic for around 20 different sarcomas and leukemias, including myxoid liposarcoma (MLS) and Ewing sarcoma (EWS). FET oncoprot...

ORGANISM(S): Homo sapiens (Human)

2025-09-22 | PXD047503 | Pride

Linker-free PROTACs efficiently induce the degradation of oncoproteins

ORGANISM(S): Homo Sapiens

2025-01-20 | PXD060001 |

Induced Degradation of Lineage-specific Oncoproteins Underlies the Selective PARP1 Inhibitor Toxicity in Small Cell Lung Cancer

A subset of small cell lung cancer (SCLC) shows a clinical response to PARP inhibitors (PARPi) despite being proficient in homologous repair pathways. However, the underlying mechanism(s) of PARPi sensitivity is poorly understood. We performed quantitative proteomic analyses and identified proteomic...

ORGANISM(S): Homo sapiens (Human)

2024-01-26 | PXD029972 | Pride

Quantitative proteomics Ascl1 Lineage-specific oncoproteins Synergistic effect Pips Parp1 inhibitor Predictive biomarkers A histone demethylase Brca1/2 Small cell lung cancer Homologous recombination

Induced Degradation of Lineage-specific Oncoproteins Underlies the Selective PARP1 Inhibitor Toxicity in Small Cell Lung Cancer (batch2-6)

ORGANISM(S): Homo sapiens (Human)

2024-01-26 | PXD029968 | Pride

Quantitative proteomics Ascl1 Lineage-specific oncoproteins Synergistic effect Pips Parp1 inhibitor Predictive biomarkers A histone demethylase Brca1/2 Small cell lung cancer Homologous recombination

KMT2A oncoproteins induce epigenetic resistance to targeted therapies.

PRJNA1060315 | ENA

EWSR1::FLI1 fusion oncoproteins’ regulation of ETS1 (ChIP-seq)

PRJNA1016476 | ENA

EWSR1::FLI1 fusion oncoproteins’ regulation of ETS1 (RNA-seq)